Japan Blood Grouping and Phenotyping Reagents Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Antisera Reagents, Red Blood Cell Reagents, Anti-Human Globulin Reagents, and Others), By Technique (PCR-based, Microarray-based, Massively Parallel Sequencing, and Others), By End-User (Hospitals, Blood Banks, Diagnostic Laboratories, and Others), and Japan Blood Grouping and Phenotyping Reagents Market Insights, Industry Trend, Forecasts to 2035

Japan Blood Grouping and Phenotyping Reagents Market Size Insights Forecasts to 2035

• The Japan Blood Grouping and Phenotyping Reagents Market Size is Expected to Grow at a CAGR of 6.8% from 2025 to 2035
• The Japan Blood Grouping and Phenotyping Reagents Market Size is Expected to Hold a Significant Share by 2035

According to a Research Report Published by Spherical Insights & Consulting, the Japan Blood Grouping and Phenotyping Reagents Market Size is expected to hold a significant share by 2035, at a CAGR of 6.8% during the forecast period 2025-2035. The Japan market for blood grouping and phenotyping reagents is growing owing to the increasing transfusion requirements from chronic disorders and operations, technological improvements, and government-sponsored blood safety initiatives. Growing public education and reagent development for uncommon blood types also aid in market growth.

Market Overview

The Japan blood grouping and phenotyping reagents market refers to the biochemical substances used in RBC typing for blood, antigen typing, antibody screening, and compatibility testing, all crucial elements of safe blood transfusion, organ transplantation, and diagnostic processes. The strengths of Japan are its advanced healthcare infrastructure, advanced laboratory facilities, and robust regulations. Opportunities in the market involve creating upcoming generation reagents for pure unique blood types, blending molecular diagnostics with serological tests, and AI-enabled workflows for improved throughput and precision. The Japanese market is stimulated by strong demand for transfusions caused by chronic diseases, hematologic malignancies, and an aging population, combined with strict compatibility testing requirements necessitating comprehensive antigen profiling for frequently transfused patients. Government programs, implemented through the Pharmaceuticals and Medical Devices Act and PMDA regulatory control, provide strict approval procedures, quality control, and reimbursement schemes within the national health insurance system for safe deployment of reagents in medical facilities.

Report Coverage

This research report categorizes the market for the Japan blood grouping and phenotyping reagents market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan blood grouping and phenotyping reagents market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan blood grouping and phenotyping reagents market.

Driving Factors

The growing aging population, increasing need for safe blood transfusions, and growing prevalence of chronic and hematologic diseases drive the Japanese blood grouping and phenotyping reagents market. Strict safety norms and advanced healthcare facilities facilitate mass-scale adoption of precise blood typing techniques. Technological innovations, such as automation and molecular diagnostics integration, increase testing accuracy and effectiveness. Growing awareness of transfusion safety and wider utilization of reagents in organ transplantations and prenatal diagnosis also drive market expansion.

Restraining Factors

The Japan blood grouping and phenotyping reagents market is confronted with challenges like high expenses of sophisticated reagents and machines, scarce skilled staff, and slow uptake in small healthcare units due to financial constraints and the absence of infrastructure.

Market Segmentation

The Japan blood grouping and phenotyping reagents market share is classified into product type, technique, and end-user.

• The antisera reagents segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan blood grouping and phenotyping reagents market is segmented by product type into antisera reagents, red blood cell reagents, anti-human globulin reagents, and others. Among these, the antisera reagents segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to their importance for the detection of individual blood group antigens, making them a necessary product for routine typing of blood and transfusion compatibility. Their effectiveness and accuracy in detecting antigens ensure against transfusion-associated complications, creating steady demand in healthcare and blood bank environments.

• The PCR-based segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan blood grouping and phenotyping reagents market is segmented by technique into PCR-based, microarray-based, massively parallel sequencing, and others. Among these, the PCR-based segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is owing to their high specificity and sensitivity and capacity to amplify small amounts of DNA. Such methods are critical for the determination of rare blood group antigens and transfusion compatibility, and are now widely applied in routine phenotyping and typing of blood.

• The hospitals segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan blood grouping and phenotyping reagents market is segmented by end-user into hospitals, blood banks, diagnostic laboratories, and others. Among these, the hospitals segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the large number of transfusions and the requirement for proper typing of blood in surgical and medical procedures. Increased surgeries, chronic illnesses, and stringent transfusion safety measures further drive reagent consumption within hospitals throughout Japan.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan blood grouping and phenotyping reagents market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sysmex Corporation
• JMS Co., Ltd.
• Eiken Chemical Co., Ltd.
• Fujirebio
• Beckman Coulter
• Bio-Rad Laboratories
• Haemokinesis Pty Ltd
• Immucor, Inc.
• Ortho Clinical Diagnostics
• Merck KGaA
• Grifols
• Kawasumi Laboratories, Inc.
• Others

Recent Developments:

• In December 2023, Sysmex Corporation expanded its blood test reagents for detecting Amyloid Beta accumulation, linked to Alzheimer’s disease, to Europe in January 2024. After successful launches in Japan and the U.S., Sysmex plans to broaden its testing parameters and accelerate the growth of its immunochemistry testing business across Europe.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan blood grouping and phenotyping reagents market based on the below-mentioned segments:

Japan Blood Grouping and Phenotyping Reagents Market, By Product Type

• Antisera Reagents
• Red Blood Cell Reagents
• Anti-Human Globulin Reagents
• Others

Japan Blood Grouping and Phenotyping Reagents Market, By Technique

• PCR-based
• Microarray-based
• Massively Parallel Sequencing
• Others

Japan Blood Grouping and Phenotyping Reagents Market, By End-User

• Hospitals
• Blood Banks
• Diagnostic Laboratories
• Others